v3.25.2

Condensed consolidated statement of loss and other comprehensive income - EUR (€)	3 Months Ended		6 Months Ended
	Jun. 30, 2025	Jun. 30, 2024	Jun. 30, 2025	Jun. 30, 2024
Profit or loss [abstract]
Research and development expenses	€ (29,607,908)	€ (23,067,934)	€ (60,522,301)	€ (41,580,950)
General and administrative expenses	(10,765,189)	(11,314,067)	(22,037,107)	(21,112,910)
Total operating expenses	(40,373,097)	(34,382,001)	(82,559,408)	(62,693,860)
Finance (expense)/income	(4,904,807)	4,721,551	(8,756,652)	5,299,771
Loss before income tax	(45,277,904)	(29,660,450)	(91,316,060)	(57,394,089)
Income taxes	(202,782)	(70,623)	(505,449)	(355,740)
Net Loss	(45,480,686)	(29,731,073)	(91,821,509)	(57,749,829)
Items that may be reclassified to profit or loss:
Exchange (losses) gains arising on translation of foreign operations	(261,162)	21,106	(389,917)	56,739
Total comprehensive loss attributable to:
Equity holders of the Company	€ (45,741,848)	€ (29,709,967)	€ (92,211,426)	€ (57,693,090)
Loss per share attributable to the equity holders of the Company during the periods
Basic loss per share	€ (0.83)	€ (0.55)	€ (1.68)	€ (1.07)
Diluted loss per share	€ (0.83)	€ (0.55)	€ (1.68)	€ (1.07)

The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 33
-IssueDate 2024-01-01
-Paragraph 66
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_66&doctype=Standard
-URIDate 2024-03-27

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 33
-IssueDate 2024-01-01
-Paragraph 67
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_67&doctype=Standard
-URIDate 2024-03-27

Pharvaris N.V. 6-K